• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

TLR 对 SARS-CoV-2 感染反应的最新研究进展概述及 TLR 激动剂作为 SARS-CoV-2 疫苗佐剂的潜力。

An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants.

机构信息

Transboundary Animal Diseases Centre, Joint Faculty of Veterinary Medicine, Kagoshima University, Kagoshima 890-0065, Japan.

Department of Microbiology and Public Health, Faculty of Animal Science and Veterinary Medicine, Patuakhali Science and Technology University, Barishal 8210, Bangladesh.

出版信息

Viruses. 2021 Nov 18;13(11):2302. doi: 10.3390/v13112302.

DOI:10.3390/v13112302
PMID:34835108
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8622245/
Abstract

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to coronavirus disease (COVID-19), a global health pandemic causing millions of deaths worldwide. However, the immunopathogenesis of COVID-19, particularly the interaction between SARS-CoV-2 and host innate immunity, remains unclear. The innate immune system acts as the first line of host defense, which is critical for the initial detection of invading pathogens and the activation and shaping of adaptive immunity. Toll-like receptors (TLRs) are key sensors of innate immunity that recognize pathogen-associated molecular patterns and activate downstream signaling for pro-inflammatory cytokine and chemokine production. However, TLRs may also act as a double-edged sword, and dysregulated TLR responses may enhance immune-mediated pathology, instead of providing protection. Therefore, a proper understanding of the interaction between TLRs and SARS-CoV-2 is of great importance for devising therapeutic and preventive strategies. The use of TLR agonists as vaccine adjuvants for human disease is a promising approach that could be applied in the investigation of COVID-19 vaccines. In this review, we discuss the recent progress in our understanding of host innate immune responses in SARS-CoV-2 infection, with particular focus on TLR response. In addition, we discuss the use of TLR agonists as vaccine adjuvants in enhancing the efficacy of COVID-19 vaccine.

摘要

严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)的出现导致了冠状病毒病(COVID-19),这是一种全球性的健康大流行,在全球范围内造成数百万人死亡。然而,COVID-19 的免疫发病机制,特别是 SARS-CoV-2 与宿主固有免疫之间的相互作用,仍不清楚。固有免疫系统作为宿主防御的第一道防线,对于初始检测入侵病原体以及激活和塑造适应性免疫至关重要。Toll 样受体(TLR)是固有免疫的关键传感器,可识别病原体相关分子模式,并激活下游信号转导,以产生促炎细胞因子和趋化因子。然而,TLR 也可能是一把双刃剑,失调的 TLR 反应可能会增强免疫介导的病理,而不是提供保护。因此,正确理解 TLR 与 SARS-CoV-2 的相互作用对于制定治疗和预防策略非常重要。TLR 激动剂作为人类疾病疫苗佐剂的使用是一种很有前途的方法,可应用于 COVID-19 疫苗的研究。在这篇综述中,我们讨论了宿主固有免疫反应在 SARS-CoV-2 感染中的最新研究进展,特别关注 TLR 反应。此外,我们还讨论了 TLR 激动剂作为疫苗佐剂在增强 COVID-19 疫苗功效方面的应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bf5/8622245/2e7fa78114a8/viruses-13-02302-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bf5/8622245/2e7fa78114a8/viruses-13-02302-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2bf5/8622245/2e7fa78114a8/viruses-13-02302-g001.jpg

相似文献

1
An Overview of Recent Insights into the Response of TLR to SARS-CoV-2 Infection and the Potential of TLR Agonists as SARS-CoV-2 Vaccine Adjuvants.TLR 对 SARS-CoV-2 感染反应的最新研究进展概述及 TLR 激动剂作为 SARS-CoV-2 疫苗佐剂的潜力。
Viruses. 2021 Nov 18;13(11):2302. doi: 10.3390/v13112302.
2
Toll-Like Receptor 3 Signaling via TRIF Contributes to a Protective Innate Immune Response to Severe Acute Respiratory Syndrome Coronavirus Infection.通过TRIF的Toll样受体3信号传导有助于对严重急性呼吸综合征冠状病毒感染产生保护性先天免疫反应。
mBio. 2015 May 26;6(3):e00638-15. doi: 10.1128/mBio.00638-15.
3
Toll-Like Receptor Signaling in Severe Acute Respiratory Syndrome Coronavirus 2-Induced Innate Immune Responses and the Potential Application Value of Toll-Like Receptor Immunomodulators in Patients With Coronavirus Disease 2019.Toll样受体信号通路在严重急性呼吸综合征冠状病毒2诱导的固有免疫反应中的作用以及Toll样受体免疫调节剂在2019冠状病毒病患者中的潜在应用价值
Front Microbiol. 2022 Jun 27;13:948770. doi: 10.3389/fmicb.2022.948770. eCollection 2022.
4
Current Understanding of the Innate Control of Toll-like Receptors in Response to SARS-CoV-2 Infection.目前对 SARS-CoV-2 感染中 Toll 样受体先天控制的理解。
Viruses. 2021 Oct 22;13(11):2132. doi: 10.3390/v13112132.
5
TLRs: Innate Immune Sentries against SARS-CoV-2 Infection.TLRs:对抗 SARS-CoV-2 感染的先天免疫哨兵。
Int J Mol Sci. 2023 Apr 29;24(9):8065. doi: 10.3390/ijms24098065.
6
Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.基于 SARS-CoV-2 的免疫原性结构蛋白、宿主免疫反应和群体免疫的 COVID-19 疫苗开发的新见解。
Cells. 2021 Oct 29;10(11):2949. doi: 10.3390/cells10112949.
7
Role of Toll-like receptors in the pathogenesis of COVID-19.Toll 样受体在 COVID-19 发病机制中的作用。
J Med Virol. 2021 May;93(5):2735-2739. doi: 10.1002/jmv.26826. Epub 2021 Feb 9.
8
STING agonists as promising vaccine adjuvants to boost immunogenicity against SARS-related coronavirus derived infection: possible role of autophagy.STING 激动剂作为有前途的疫苗佐剂,可增强针对 SARS 相关冠状病毒感染的免疫原性:自噬的可能作用。
Cell Commun Signal. 2024 Jun 3;22(1):305. doi: 10.1186/s12964-024-01680-0.
9
Role of toll-like receptors in the pathogenesis of COVID-19: Current and future perspectives. Toll 样受体在 COVID-19 发病机制中的作用:现状与展望。
Scand J Immunol. 2023 Aug;98(2):e13275. doi: 10.1111/sji.13275. Epub 2023 May 7.
10
Adjuvants for Coronavirus Vaccines.冠状病毒疫苗佐剂。
Front Immunol. 2020 Nov 6;11:589833. doi: 10.3389/fimmu.2020.589833. eCollection 2020.

引用本文的文献

1
Toll-like Receptor (TLR) Response in Chikungunya Virus Infection: Mechanism of Activation, Immune Evasion, and Use of TLR Agonists in Vaccine Development.基孔肯雅病毒感染中的Toll样受体(TLR)反应:激活机制、免疫逃逸以及TLR激动剂在疫苗开发中的应用
Vaccines (Basel). 2025 Aug 13;13(8):856. doi: 10.3390/vaccines13080856.
2
Innate Immune Response to Powassan Virus Infection: Progress Toward Infection Control.对波瓦桑病毒感染的先天免疫反应:感染控制方面的进展
Vaccines (Basel). 2025 Jul 15;13(7):754. doi: 10.3390/vaccines13070754.
3
Toll-like receptor response to Zika virus infection: progress toward infection control.

本文引用的文献

1
SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-κB pathway.SARS-CoV-2 刺突蛋白通过 TLR2 依赖性激活 NF-κB 途径诱导炎症反应。
Elife. 2021 Dec 6;10:e68563. doi: 10.7554/eLife.68563.
2
SARS-CoV-2, COVID-19 and the Ageing Immune System.SARS-CoV-2、COVID-19 和衰老的免疫系统。
Nat Aging. 2021 Sep;1(9):769-782. doi: 10.1038/s43587-021-00114-7. Epub 2021 Sep 14.
3
Toll-Like Receptor Response to Hepatitis B Virus Infection and Potential of TLR Agonists as Immunomodulators for Treating Chronic Hepatitis B: An Overview.
Toll样受体对寨卡病毒感染的反应:感染控制方面的进展
Npj Viruses. 2025 Mar 13;3(1):20. doi: 10.1038/s44298-025-00102-3.
4
Immunity and Coagulation in COVID-19.新型冠状病毒肺炎中的免疫与凝血。
Int J Mol Sci. 2024 Oct 19;25(20):11267. doi: 10.3390/ijms252011267.
5
Special Issue "The Role of Toll-Like Receptors (TLRs) in Infection and Inflammation 2.0".特刊:“Toll 样受体(TLRs)在感染和炎症中的作用 2.0”
Int J Mol Sci. 2024 Sep 7;25(17):9709. doi: 10.3390/ijms25179709.
6
Recent Insights into the Molecular Mechanisms of the Toll-like Receptor Response to Influenza Virus Infection.近期对 Toll 样受体(TLR)响应流感病毒感染的分子机制的深入了解。
Int J Mol Sci. 2024 May 29;25(11):5909. doi: 10.3390/ijms25115909.
7
Immune Epitopes of SARS-CoV-2 Spike Protein and Considerations for Universal Vaccine Development.SARS-CoV-2 刺突蛋白的免疫表位及通用疫苗开发的考虑因素。
Immunohorizons. 2024 Mar 1;8(3):214-226. doi: 10.4049/immunohorizons.2400003.
8
TLR agonists as vaccine adjuvants in the prevention of viral infections: an overview.Toll样受体激动剂作为预防病毒感染的疫苗佐剂:概述
Front Microbiol. 2023 Dec 21;14:1249718. doi: 10.3389/fmicb.2023.1249718. eCollection 2023.
9
Immunogenicity and safety of adjuvant-associated COVID-19 vaccines: A systematic review and meta-analysis of randomized controlled trials.佐剂相关新冠疫苗的免疫原性和安全性:随机对照试验的系统评价与荟萃分析
Heliyon. 2023 Nov 28;9(12):e22858. doi: 10.1016/j.heliyon.2023.e22858. eCollection 2023 Dec.
10
Immune Epitopes of SARS-CoV-2 Spike Protein and Considerations for Universal Vaccine Development.严重急性呼吸综合征冠状病毒2刺突蛋白的免疫表位与通用疫苗研发的考量
bioRxiv. 2023 Oct 27:2023.10.26.564184. doi: 10.1101/2023.10.26.564184.
Toll 样受体对乙型肝炎病毒感染的反应及 TLR 激动剂作为治疗慢性乙型肝炎免疫调节剂的潜力:综述。
Int J Mol Sci. 2021 Sep 28;22(19):10462. doi: 10.3390/ijms221910462.
4
COVID-19 Subunit Vaccine with a Combination of TLR1/2 and TLR3 Agonists Induces Robust and Protective Immunity.含TLR1/2和TLR3激动剂组合的COVID-19亚单位疫苗可诱导强大的保护性免疫。
Vaccines (Basel). 2021 Aug 27;9(9):957. doi: 10.3390/vaccines9090957.
5
Cytokine Response to SARS-CoV-2 Infection in Children.儿童感染 SARS-CoV-2 的细胞因子反应。
Viruses. 2021 Sep 18;13(9):1868. doi: 10.3390/v13091868.
6
Distinct single-component adjuvants steer human DC-mediated T-cell polarization via Toll-like receptor signaling toward a potent antiviral immune response.不同的单一成分佐剂通过 Toll 样受体信号通路引导人树突状细胞介导的 T 细胞极化,从而产生有效的抗病毒免疫反应。
Proc Natl Acad Sci U S A. 2021 Sep 28;118(39). doi: 10.1073/pnas.2103651118.
7
Infrared light therapy relieves TLR-4 dependent hyper-inflammation of the type induced by COVID-19.红外光疗法可缓解由新冠病毒引起的TLR-4依赖性过度炎症。
Commun Integr Biol. 2021 Sep 15;14(1):200-211. doi: 10.1080/19420889.2021.1965718. eCollection 2021.
8
Case report: hepatitis in a child infected with SARS-CoV-2 presenting toll-like receptor 7 Gln11Leu single nucleotide polymorphism.病例报告:感染 SARS-CoV-2 的儿童中出现 Toll 样受体 7 Gln11Leu 单核苷酸多态性导致的肝炎。
Virol J. 2021 Sep 5;18(1):180. doi: 10.1186/s12985-021-01656-3.
9
Differential plasmacytoid dendritic cell phenotype and type I Interferon response in asymptomatic and severe COVID-19 infection.无症状和重症 COVID-19 感染中的浆细胞样树突状细胞表型和 I 型干扰素反应的差异。
PLoS Pathog. 2021 Sep 2;17(9):e1009878. doi: 10.1371/journal.ppat.1009878. eCollection 2021 Sep.
10
Platelet Innate Immune Receptors and TLRs: A Double-Edged Sword.血小板先天免疫受体和 TLRs:一把双刃剑。
Int J Mol Sci. 2021 Jul 23;22(15):7894. doi: 10.3390/ijms22157894.